Quick-Onset Nasal Delivery of Tramadol for the Treatment of Pain

Touitou Elka, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research

New Nasal Technology for Pain Treatment


Pain treatment

Development Stage

Results in animal model  for a non-opiate drug, industrial scale up formulation

Results in animal model  for a new drug combination  in treatment of pain


  • Currently, few prescription non-opiate pain drugs achieve acceptable analgesia in more than 50% of treated patients.
  • The new treatments could improve opiate and non-opiate pain therapy

Our Innovation

  • Carrier for enhanced nasal absorption
  • Improved treatment using a formulation based on the IP carrier

Key Features

The drug formulation based on the new carrier:

  • may be administered as nasal drops, spray, aerosol, nebulizer or in a semi-solid preparation such as gel, cream or ointment
  • Contains FDA approved ingredients

Development Milestones

  • Results in animals

The Opportunity

  • Huge market - worldwide, millions of people suffer daily from pain; more than 11 million Americans report pain as a significant disability
  • Opportunity for new and improved formulations for opiate and non-opiate drugs

Patent Status

Granted US 8,911,751; China 101325944; Europe 1933809; India 263700; Israel 190566; Japan 5362360

Contact for more information:

Shani Bullock
VP, Business Development, Healthcare
Contact ME: